Boston Scientific to Acquire Symetis

Medical Devices Directory Forums Business Partnering Boston Scientific to Acquire Symetis

This topic contains 0 replies, has 1 voice, and was last updated by  Global Medtech 7 months, 3 weeks ago.

Viewing 1 post (of 1 total)
  • Author
    Posts
  • #4562 Reply

    Global Medtech
    Participant

    Boston Scientific announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices, for $435 million in up-front cash.

    The Symetis portfolio includes the ACURATE TA™ and ACURATE neo/TF valve* systems for use in the treatment of high-risk patients suffering from severe and symptomatic aortic valve stenosis, which are sold in Europe and in other geographies outside of the United States. Symetis is also developing the ACURATE neo/AS** next generation valve system, currently in a clinical trial intended to serve as the basis for a future CE mark application.

    This agreement to acquire Symetis follows the recent acquisition by Boston Scientific of certain Neovasc, Inc. manufacturing assets, and demonstrates the company’s continued investment in structural heart through intellectual property, research and development, and manufacturing capabilities.announced

    Share
Viewing 1 post (of 1 total)
Reply To: Boston Scientific to Acquire Symetis
Your information:




Share